MAP2K7 and craniopharyngioma: Brastianos et al. reported a case where a male patient with recurrent craniopharyngioma, harboring a BRAF-V600E mutation, was treated with a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib [93].